Thrombotic Thrombocytopenic Purpura – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Thrombotic Thrombocytopenic Purpura – Pipeline Review, H2 2016’, provides an overview of the Thrombotic Thrombocytopenic Purpura pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura

The report reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Thrombotic Thrombocytopenic Purpura therapeutics and enlists all their major and minor projects

The report assesses Thrombotic Thrombocytopenic Purpura therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Thrombotic Thrombocytopenic Purpura

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ablynx NV

Biogen Inc

Glenmark Pharmaceuticals Ltd.

Hansa Medical AB

Kaketsuken K.K.

Lee's Pharmaceutical Holdings Limited

Octapharma AG

Omeros Corporation

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Thrombotic Thrombocytopenic Purpura Overview 7

Therapeutics Development 8

Pipeline Products for Thrombotic Thrombocytopenic Purpura - Overview 8

Pipeline Products for Thrombotic Thrombocytopenic Purpura - Comparative Analysis 9

Thrombotic Thrombocytopenic Purpura - Therapeutics under Development by Companies 10

Thrombotic Thrombocytopenic Purpura - Therapeutics under Investigation by Universities/Institutes 11

Thrombotic Thrombocytopenic Purpura - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Thrombotic Thrombocytopenic Purpura - Products under Development by Companies 15

Thrombotic Thrombocytopenic Purpura - Products under Investigation by Universities/Institutes 16

Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development 17

Ablynx NV 17

Biogen Inc 18

Glenmark Pharmaceuticals Ltd. 19

Hansa Medical AB 20

Kaketsuken K.K. 21

Lee's Pharmaceutical Holdings Limited 22

Octapharma AG 23

Omeros Corporation 24

Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

ARC-15105 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

BAX-930 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

caplacizumab - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

GBR-600 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

OMS-721 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

plasma (human) - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

rituximab - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ZK-001 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Thrombotic Thrombocytopenic Purpura - Dormant Projects 60

Thrombotic Thrombocytopenic Purpura - Product Development Milestones 61

Featured News & Press Releases 61

Oct 11, 2016: First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura 61

Sep 29, 2016: Ablynx First-In-Class Wholly-Owned Anti-vWF Nanobody, Caplacizumab, May Have The Potential To Reduce Morbidity And Mortality Associated With Acquired TTP 61

May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association 62

Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP 63

Sep 29, 2015: Ablynx Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP 64

Jun 17, 2015: Ablynx Announces Presentations On Its Potential First-In-Class Treatment For Acquired TTP, Caplacizumab, At The 2015 Annual Meeting Of The ISTH 64

Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use 65

Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting 66

Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab 67

Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study 68

Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 69

Jul 28, 2011: Initial Observations Of ABLYNX’S PHASE II TTP Program Presented At ISTH Congress 70

Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 71

Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 71

Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2016 8

Number of Products under Development for Thrombotic Thrombocytopenic Purpura – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Thrombotic Thrombocytopenic Purpura – Pipeline by Ablynx NV, H2 2016 17

Thrombotic Thrombocytopenic Purpura – Pipeline by Biogen Inc, H2 2016 18

Thrombotic Thrombocytopenic Purpura – Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 19

Thrombotic Thrombocytopenic Purpura – Pipeline by Hansa Medical AB, H2 2016 20

Thrombotic Thrombocytopenic Purpura – Pipeline by Kaketsuken K.K., H2 2016 21

Thrombotic Thrombocytopenic Purpura – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 22

Thrombotic Thrombocytopenic Purpura – Pipeline by Octapharma AG, H2 2016 23

Thrombotic Thrombocytopenic Purpura – Pipeline by Omeros Corporation, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Thrombotic Thrombocytopenic Purpura – Dormant Projects, H2 2016 60

List of Figures

List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2016 8

Number of Products under Development for Thrombotic Thrombocytopenic Purpura – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports